Researchers are increasingly turning to artificial intelligence to simulate clinical trials entirely inside computers — a process known as in-silico testing — as a faster, cheaper path to finding new uses for existing drugs.
The approach, highlighted by Applied Clinical Trials Online, centers on drug repurposing: taking medicines already approved for one condition and using AI models to predict whether they might work for another. Because these drugs have already cleared safety reviews, the path to actual patient use can be significantly shorter than developing a new compound from scratch.
In-silico trials allow scientists to run thousands of virtual experiments without the cost or time of enrolling human participants in early-stage studies. AI systems analyze biological data, patient records, and molecular interactions to flag which existing drugs show the most promise for new applications before anyone enters a lab.
The push is not limited to repurposing. According to reporting from MSN, AI is becoming increasingly embedded across clinical trial operations more broadly — including in oncology, where the complexity of cancer biology makes finding the right treatment combinations especially difficult. Sponsors running these trials, the report notes, must find effective ways to implement the technology to get the most value from it, suggesting that adoption comes with real operational challenges.
The convergence of these two trends — AI-simulated trials and AI-assisted trial management — points to a deeper transformation in how new treatments reach patients. The stakes are high: drug development typically takes over a decade and costs billions of dollars, and most candidates fail. If AI can reliably narrow the field before human trials begin, it could meaningfully cut both the timeline and the attrition rate that makes medicine so expensive to develop.